EUVIMEDOpdag EUVIMED
MetaanalyseSystematische ÜbersichtOpen access · CC BY-NC-ND 4.0

Real‐World Effectiveness and Safety of JAK Inhibitors in Atopic Dermatitis: A Systematic Review and Meta‐Analysis

Yunha Kim iD, Gayeong Seo iD, Jacob J E Koopman iD, Jeong Yee iD

Clinical & Experimental Allergy · 2025-09 · 55 (9) · 755-772

DOI: 10.1111/cea.70125 ↗

At a glance

Metaanalyse in Clinical & Experimental Allergy, published online on 2025-08-02. Written by Yunha Kim and 3 co-authors. Institution: School of Pharmacy, Sungkyunkwan University, Suwon, Republic of Korea. Major MEDLINE topics: Dermatitis, Atopic, Janus Kinase Inhibitors. Cited 15 times so far (Crossref); 87 references. The full text is freely available (open access, CC BY-NC-ND 4.0).

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Objective

The aim of this study is to evaluate the effectiveness and safety of JAK inhibitors in patients with moderate to severe atopic dermatitis by performing a systematic review and meta‐analysis using data from studies in real‐world settings.

Design

Systematic review and meta‐analysis. Pooled estimates for effectiveness and safety were assessed using the Freeman–Tukey Double ArcSine method. Statistical heterogeneity was assessed using I 2 statistics. A random‐effects model (DerSimonian‐Laird method) was applied to consider the heterogeneity within and between studies and to give a more conservative estimate. The study quality assessment tools developed by the National Heart, Lung, and Blood Institute were used. Data Source Relevant studies were searched in March 2025 using four databases: PubMed, Embase, Scopus, and Web of Science. Eligibility Criteria Studies evaluating the effectiveness or safety of systemic JAK inhibitors among patients with moderate to severe atopic dermatitis in a real‐world setting were included.

Results

A total of 50 studies were included in this review. Regarding their effectiveness, the pooled estimates with a 95% CI of Eczema Area and Severity Index (EASI)‐75 were 44% (34%–55%), 45% (28%–62%), 59% (51%–66%), 73% (64%–81%), 70% (57%–81%), and 86% (72%–96%) at 4, 8, 12, 16, 24, and 52 weeks. For safety, the most common adverse events were acne (16%), followed by increased creatine phosphokinase levels (13%) and increased lipids (12%).

Conclusion

Our meta‐analysis of JAK inhibitors in patients with atopic dermatitis demonstrated that the overall outcomes from real‐world settings are comparable to those from clinical trials. Systematic Review Registration Protocol Registration: PROSPERO CRD42024569258.

Subjects

MeSH terms (MEDLINE)

Dermatitis, AtopicJanus Kinase InhibitorsHumansSeverity of Illness IndexTreatment Outcome

Author keywords

Janus kinase inhibitorsabrocitinibatopic dermatitisbaricitinibreal‐world dataupadacitinib

Substances

Janus Kinase Inhibitors

Authors and institutions

  • School of Pharmacy, Sungkyunkwan University, Suwon, Republic of Korea.
  • Division of Rheumatology, Inflammation and Immunity, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.

ORCID profiles: Yunha Kim, Gayeong Seo, Jacob J E Koopman, Jeong Yee

Cite

APA

Kim, Y., Seo, G., Koopman, J. J. E., & Yee, J. (2025). Real‐World Effectiveness and Safety of JAK Inhibitors in Atopic Dermatitis: A Systematic Review and Meta‐Analysis. Clinical & Experimental Allergy, 55(9), 755-772. https://doi.org/10.1111/cea.70125

Vancouver

Kim Y, Seo G, Koopman JJE, Yee J. Real‐World Effectiveness and Safety of JAK Inhibitors in Atopic Dermatitis: A Systematic Review and Meta‐Analysis. Clinical & Experimental Allergy. 2025;55(9):755-772. doi:10.1111/cea.70125

BibTeX
@article{Kim2025,
  author = {Kim, Yunha and Seo, Gayeong and Koopman, Jacob J E and Yee, Jeong},
  title = {Real‐World Effectiveness and Safety of JAK Inhibitors in Atopic Dermatitis: A Systematic Review and Meta‐Analysis},
  journal = {Clinical & Experimental Allergy},
  year = {2025},
  volume = {55},
  number = {9},
  pages = {755--772},
  doi = {10.1111/cea.70125}
}
Start for free →